Ginkgo Bioworks Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jason Kelly
- Full Time Employees
- 485
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 27 Drydock Avenue Boston MA United States 02210
- IPO Date
- Apr 19, 2021
- CIK
- 0001830214
- Website
- ginkgo.bio
- Similar Companies
- Business
- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) operates as a leading synthetic biology company that develops a cell programming platform enabling customers to engineer organisms for applications across pharmaceuticals, biotechnology, agriculture, industrial biotech, food and nutrition, consumer products, and biosecurity; its core offerings include cell engineering research and development solutions such as functional genomics, antibody developability services, artificial intelligence models, reconfigurable automation systems, strain improvement for optimized microorganism production, Ginkgo Enzyme Services encompassing novel enzyme discovery, high-expression host strains like methanol-free Pichia pastoris and low-viscosity Aspergillus niger, fermentation process development with Ambr 250 bioreactors, and manufacturing scale-up up to 3,000L capacity, as well as biosecurity services through Canopy for biomonitoring and genomic data generation and Horizon for digital surveillance and biothreat detection. Founded in 2008 and headquartered at 27 Drydock Avenue in Boston, Massachusetts, the company serves diverse industries including government and defense via its two main segments of Cell Engineering and Biosecurity, with operations centered in the United States and facilities supporting global partnerships. Recent developments include the launch of Ginkgo Enzyme Services to advance enzyme R&D for pharmaceuticals, diagnostics, food, agriculture, and materials through ultra-high-throughput screening and machine learning-guided protein design; a multi-year extension of its strategic partnership with Bayer, originally established in 2017, to develop microbial nitrogen fixation, biological crop protection, and carbon sequestration solutions for sustainable agriculture, with Bayer retaining commercialization rights; and prior acquisitions such as FGen AG's screening platform in 2022 and Reverie Labs platform in 2024 to enhance its bioengineering capabilities.
Company News
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Ginkgo Bioworks Q3 Earnings Call Highlights
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.
Hugging Face is launching a new AI model that lets scientists 'chat with DNA'
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
What's Going on With Ginkgo Bioworks Stock on Friday?
Araceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von Nebula
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebula
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ginkgo Bioworks (NYSE:DNA) Hits New 1-Year High – Time to Buy?
Ginkgo Bioworks (NYSE:DNA) Sees Unusually-High Trading Volume – Should You Buy?
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know